Scienza e Tecnologia
New randomized controlled trial shows that addition of Smith+Nephew's REGENETEN™ Bioinductive Implant delivers 86% reduction in rotator cuff re-tear rates at 12 months
At 12 months follow-up, repairs with the added REGENETEN Bioinductive Implant resulted in significantly lower re-tear rates than those with a TOE repair alone (p= 0.022). Specifically, the RCT reported:
There were no differences in postoperative complications between groups.
"Traditional rotator cuff procedures and the resulting re-tear rates present a challenge and a concern for both surgeons and patients alike," commented Prof. Ruiz-Ibán. "The interim results from this RCT are encouraging and indicate that the Smith+Nephew REGENETEN Bioinductive Implant may significantly improve re-tear rates. I look forward to the completion of this investigation in 2023 and further use of the implant."
With the potential to aid approximately 545,000 annual rotator cuff procedures, globally , the REGENETEN Bioinductive Implant provides a patient centric treatment supporting the body's natural healing response to facilitate healing of rotator cuff tears. With at least 12 published clinical studies including 709 patients , the REGENETEN implant has been shown to change the course of tear progression in early studies , aid return to normal activity and reduce re-tears versus conventional surgery.
"New RCT evidence supporting the use of our REGENETEN™ Bioinductive Implant for improved patient outcomes continues to grow," said Christie Van Geffen , VP Sports Medicine Joint Repair at Smith+Nephew. "No other bioinductive treatment has the amount of science behind it supporting the clinical value for thousands of patients with rotator cuff tears."
The REGENETEN Bioinductive Implant is part of Smith+Nephew's comprehensive Advanced Healing Solutions portfolio - redefining biological healing in rotator cuff repair along with expanded applications for Gluteus Medius and Achilles tears. To learn more about the REGENETEN Bioinductive Implant, please click here.
*The REGENETEN implant is currently approved for use in treating Gluteus Medius and Achilles tears only in the U.S.
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK , in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE: SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter , LinkedIn , Instagram or Facebook .
Photo: https://mma.prnewswire.com/media/1896761/Smith_Nephews_REGENETEN_Bioinductive_Implant.jpg
Logo: https://mma.prnewswire.com/media/3924/Smith_Nephew_Logo.jpg